Open Access

Human non‑small cell lung cancer cells can be sensitized to camptothecin by modulating autophagy

  • Authors:
    • Yi-Han Chiu
    • Shih-Hsien Hsu
    • Hsiao-Wei Hsu
    • Kuo-Chin Huang
    • Wangta Liu
    • Chang-Yi Wu
    • Wei-Pang Huang
    • Jeff Yi‑Fu Chen
    • Bing-Hung Chen
    • Chien-Chih Chiu
  • View Affiliations

  • Published online on: August 14, 2018     https://doi.org/10.3892/ijo.2018.4523
  • Pages: 1967-1979
  • Copyright: © Chiu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Lung cancer is a prevalent disease and is one of the leading causes of mortality worldwide. Despite the development of various anticancer drugs, the prognosis of lung cancer is relatively poor. Metastasis of lung cancer, as well as chemoresistance, is associated with a high mortality rate for patients with lung cancer. Camptothecin (CPT) is a well-known anticancer drug, which causes cancer cell apoptosis via the induction of DNA damage; however, the cytotoxicity of CPT easily reaches a plateau at a relatively high dose in lung cancer cells, thus limiting its efficacy. The present study demonstrated that CPT may induce autophagy in two human non‑small cell lung cancer cell lines, H1299 and H460. In addition, the results of a viability assay and Annexin V staining revealed that CPT-induced autophagy could protect lung cancer cells from programmed cell death. Conversely, the cytotoxicity of CPT was increased when autophagy was blocked by 3-methyladenine treatment. Furthermore, inhibition of autophagy enhanced the levels of CPT-induced DNA damage in the lung cancer cell lines. Accordingly, these findings suggested that autophagy exerts a protective role in CPT-treated lung cancer cells, and the combination of CPT with a specific inhibitor of autophagy may be considered a promising strategy for the future treatment of lung cancer.
View Figures
View References

Related Articles

Journal Cover

November-2018
Volume 53 Issue 5

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Chiu Y, Hsu S, Hsu H, Huang K, Liu W, Wu C, Huang W, Chen JY, Chen B, Chiu C, Chiu C, et al: Human non‑small cell lung cancer cells can be sensitized to camptothecin by modulating autophagy. Int J Oncol 53: 1967-1979, 2018
APA
Chiu, Y., Hsu, S., Hsu, H., Huang, K., Liu, W., Wu, C. ... Chiu, C. (2018). Human non‑small cell lung cancer cells can be sensitized to camptothecin by modulating autophagy. International Journal of Oncology, 53, 1967-1979. https://doi.org/10.3892/ijo.2018.4523
MLA
Chiu, Y., Hsu, S., Hsu, H., Huang, K., Liu, W., Wu, C., Huang, W., Chen, J. Y., Chen, B., Chiu, C."Human non‑small cell lung cancer cells can be sensitized to camptothecin by modulating autophagy". International Journal of Oncology 53.5 (2018): 1967-1979.
Chicago
Chiu, Y., Hsu, S., Hsu, H., Huang, K., Liu, W., Wu, C., Huang, W., Chen, J. Y., Chen, B., Chiu, C."Human non‑small cell lung cancer cells can be sensitized to camptothecin by modulating autophagy". International Journal of Oncology 53, no. 5 (2018): 1967-1979. https://doi.org/10.3892/ijo.2018.4523